A newly approved drug intended to slow the progression of Alzheimer’s disease offers patients hope, but it will come with a steep price tag: $26,500 a year.
That drug initially cost $56,000 per year before Biogen slashed the price in half, to $28,000 annually.
Dr. David Rind, the institute's chief medical officer, said an appropriate cost for the drug is $8,500 to $20,600 a year.
John Domeck, 60, of Aurora, Ohio is currently enrolled in a phase 3 clinical trial testing Leqembi.
But right now, the clinical trial for Leqembi shows that the drug provides "modest efficacy at a big, big price," Caplan said.